Search Results

Verge Genomics and Ferrer have announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis, in Europe, Central and South America, Southeast Asia, and Japan.

Verge Genomics announced today that Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference, on Wednesday, February 28th from 10:45 a.m. – 11:15 a.m. EST.

Verge Genomics announced that Verge Genomics’ co-founder and CEO, Alice Zhang, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Stem Pharm, Inc. and Verge Genomics, announced a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD).

Verge Genomics announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS).

Verge Genomics today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, announced that its Phase 1b proof-of-concept (POC) study of its lead drug candidate, VRG50635, will incorporate Modality.AI, the first automated, clinically validated, multimodal system to assess speech and language patterns